Document Detail


Hyperbaric oxygen: a novel technology for modulating myocardial schemia-reperfusion via a single drug.
MedLine Citation:
PMID:  17050495     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Over the years, the anecdotal medical use of oxygen has demonstrated, in a non-evidence-based manner, that it may have wide-ranging clinical consequences. Although oxygen is a critical substrate in the alleviation of hypoxia, anoxia, and ischemia, paradoxically, it also functions as a deleterious metabolite during the reperfusion of previously ischemic tissues. In adding to this controversy, a spate of new pioneering work has identified hyperoxygenation (hyperoxia) and its metabolites as solely and purposefully demonstrating cellular and clinical benefit,particularly in the field of ischemic reperfusion injury (IRI). Furthermore, the beneficial effects of oxygen have been technologically augmented by administration at doses above atmospheric pressure and at higher concentrations. The novel technology that involves oxygen treatment at supra-atmospheric pressures in high concentrations is known as hyperbaric oxygen (HBO). Although the concept of hyperbaric oxygen has been around since the mid 20th century, it is only during the past decade or so that its therapeutic potential as a new technology-based drug has been exploited for the purposes of cellular tolerance and protection. HBO has recently been shown to be a useful adjunct in several models of IRI, including myocardial infarction. How it does this remains to be elucidated. This article attempts to bring into the spotlight some pertinent developments regarding HBO and myocardial IRI, while simultaneously stimulating intellect, thought, and discussion as to whether this novel technology--HBO--which consists of only a singular drug--oxygen--is a therapy that warrants further laboratory and clinical investigation as a therapeutic modality that may be safe and cost-effective, without producing significant adverse effects.
Authors:
Jeysen Zivan Yogaratnam; Gerard Laden; Levant Guvendik; Mike Cowen; Alex Cale; Steve Griffin
Related Documents :
15891325 - Effect of carbon dioxide on systemic oxygenation, oxygen consumption, and blood lactate...
17050495 - Hyperbaric oxygen: a novel technology for modulating myocardial schemia-reperfusion via...
1934325 - Amrinone during porcine intraperitoneal sepsis.
1592345 - Effects of vasopressor agents and epoprostenol on systemic hemodynamics and oxygen tran...
17297315 - Effects of mannitol bolus administration on intracranial pressure, cerebral extracellul...
858175 - Volume-pressure relationships during development of mineralocorticoid hypertension in man.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Advances in therapy     Volume:  23     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2006 Jul-Aug
Date Detail:
Created Date:  2006-10-19     Completed Date:  2007-01-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  528-33     Citation Subset:  T    
Affiliation:
Department of Cardiothoracic Surgery, Castle Hill Hospital, Cottingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials as Topic
Humans
Hyperbaric Oxygenation*
Myocardial Reperfusion Injury / therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Traveler's diarrhea.
Next Document:  Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to f...